16:27 EST UroGen Pharma (URGN) files automatic mixed securities shelf
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- Urogen Pharma’s Promising Growth and Demand Surge Support Buy Rating
- UroGen Pharma reports Q3 EPS (69c), consensus (68c)
- UroGen Pharma announces preliminary results from Phase 3 UTOPIA trial
- UroGen Pharma’s UGN-104 Study: A Potential Game-Changer in Urothelial Cancer Treatment
- UroGen Pharma’s Phase 3 Study on UGN-103: A Potential Game-Changer in Bladder Cancer Treatment